Bempedoic acid
Bempedoic acid has been studied in 91 papers since 2021: 7 trials and 22 observational studies in people, 2 in animals, 57 reviews; 74 in the past year. It is an approved medicine.
27 new papers in 30 daysSee all 98 papers on bempedoic acid
At a glance
Bempedoic acid reduces cardiovascular events and LDL cholesterol in human trials, reproduced by independent labs, but increases hyperuricemia in hypercholesterolemia. An observational comparison with ezetimibe shows no clear cardiovascular-event link in statin-intolerant patients with cardiovascular-kidney-metabolic syndrome receiving GLP-1 receptor agonists for secondary prevention. Some authors work at companies, and a human paper declares ties to developer Organon.
63 findings in 31 papers from 2021 to 2026, 16 of them since May 2026
Independent labs found the same change in people. 24 independent labs in 10 countries; 117 trials, 58 about aging, 67 with no results posted.
“LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”
2 of its findings point the other way.
- 24 independent labs in 10 countries
- 2 findings against
- 117 trials, 58 about aging, 67 with no results posted
- Funders: Charite - Universitaetsmedizin Berlin and 8 more
- 25 of 52 findings with company ties
- 68 of 117 trials sponsored by its developers
- Human trial7
- Humans21
- Animals2
- In silico3
Studies in people
See all 8 studies of bempedoic acid in people8 studies gave bempedoic acid to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Lowers the risk of major adverse limb events36% down: Decreases total major adverse limb events2.9 with bempedoic acid versus 4.0 with placebo down: Lowers the risk of major adverse cardiovascular events or major adverse limb eventsHR, 0.87 [95% CI, 0.80–0.95] | Randomized trialmedian of 40.6 months | 13,970 peopleBoth18 to 85 years of agePatients 18 to 85 years of age with history of or at high risk of cardiovascular diseases who were not able to take recommended statin treatment because of intolerance | Circulation, Aug 18, 2026 |
down: Decreases LDL-C−22.75% up: Increases uric acid+0.96 mg/dL | Treated cohortmedian follow-up duration of 28 weeks (IQR 23–47 weeks) | 125 people79.2% were malemean age 62.4 ± 10.1 yearsPatients with CCS, aged ≥18 years, with LDL-C levels ≥ 55 mg/dL despite at least 8 weeks of stable intensive lipid-lowering therapy | Journal of clinical medicine, Aug 5, 2026 |
down: Decreases LDL cholesterol-18.02% (95% CI, -18.83 to -17.21) | Review of trials | 6,025 people pooledOn top of statin therapy | Journal of clinical lipidology, Feb 26, 2026 |
| Randomized trialmedian follow-up 40.6 months | 13,970 people66 ±9 yearsOlder adults; in patients with elevated steatosis scores | European journal of preventive cardiology, Feb 16, 2026 | |
down: Decreases LDL-C-19% (IQR -36.4% to -3.6%, p < 0.01) down: Decreases C-reactive protein-34.0% (p < 0.01) | Trial12 weeks | 180 peoplePatient cohorts | medRxiv, Feb 9, 2026 |
What did studies of bempedoic acid find?
23Studies of bempedoic acid measured 23 outcomes; the most studied are LDL-C (8 studies), LDL cholesterol (6) and uric acid (2).
LDL-C
downin humans8−23%
8 studies
LDL-C
downin humans8−23%
Bempedoic acid decreases LDL-C in humans (−22.75%).
“The addition of BA resulted in a significant reduction in LDL-C levels, from 71.90 ± 18.03 mg/dL to 55.54 ± 14.23 mg/dL (absolute reduction: 16.36 mg/dL; relative reduction: −22.75%; p < 0.001).”
Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118
Journal of clinical medicine
Bempedoic acid decreases LDL-C in humans (-19% (IQR -36.4% to -3.6%, p < 0.01)).
“The median percentage change in LDL-C from baseline to week 12 was -19% (interquartile range [IQR]: -36.4% to -3.6%), decreasing from 117.5 to 92 mg/dL (p < 0.01).”
Human trial12 weeksn = 180
medRxivPreprint
Bempedoic acid decreases LDL-C in humans (hypercholesterolemia) (-24.3% (95% CI -27.8 to -20.9)).
“LDL-C fell by 24.3 % (95 % CI −27.8 to −20.9)”
Human trialhypercholesterolemia
AHA Scientific Sessions 2025 abstract
Bempedoic acid is linked with lower LDL-C in humans (mean reduction 1.05 mmol/L (SD 0.15)).
“Mean LDL-C reduction across the cohort was 1.05 mmol/L (SD 0.15)”
Humans
ESC Congress 2026 abstract
Bempedoic acid is linked with lower LDL-C in humans (-22.8% (-16.36 mg/dL)).
“BA reduced LDL-C by 22.8% (-16.36 mg/dL; p < 0.001), enabling 48.3% of patients to achieve LDL-C < 55 mg/dL.”
Humansin chronic coronary syndrome patients with LDL-C ≥ 55 mg/dL despite stable intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118
Journal of clinical medicine
Bempedoic acid is linked with lower LDL-C in humans (21%, p < 0.0001).
“By 3 months, BA (21%) and BA + EZE (33%, p < 0.0001 for both) were associated with significant reductions in median LDL-C levels.”
Humans3 monthsn = 900
LDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Atherosclerosis plus
Bempedoic acid is linked with lower LDL-C in humans (compared with baseline LDL-C of 138 mg/dl) (88 vs 138 mg/dl baseline at 3 months; 92 mg/dl at 1 year).
“BA significantly lowered LDL-C levels at 3 months (88mg/dl +/- 32) (p <0.001)”
Humanscompared with baseline LDL-C of 138 mg/dlup to 1 year
SAT-263 Access to Bempedoic Acid - A Real World Assessment in an Academic Clinical Practice
ENDO 2025 abstract
Bempedoic acid decreases LDL-C in high- and very-high-risk individuals unable or unwilling to take statins.
“Bempedoic acid emerged as a generally safe, efficient, and cost-effective strategy to lower LDL-C and cardiovascular risk”
Reviewin high- and very-high-risk individuals unable or unwilling to take statins
Bempedoic Acid: From Guidelines to the Real World
Journal of lipid and atherosclerosis
Bempedoic acid decreases LDL-C in patients with elevated LDL-C.
“In domestic and international clinical studies, bempedoic acid reduced LDL-C levels in patients with elevated LDL-C, regardless of their response to statin therapy.”
Reviewin patients with elevated LDL-C
Nihon yakurigaku zasshi. Folia pharmacologica Japonica
LDL cholesterol
downin humans6
6 studies
LDL cholesterol
downin humans6
Bempedoic acid decreases LDL cholesterol in humans (on top of statin therapy) (-18.02% (95% CI, -18.83 to -17.21)).
“bempedoic acid produced a reduction of -18.02% (95% CI, -18.83 to -17.21)”
Human trialon top of statin therapy
Journal of clinical lipidology
Bempedoic acid decreases LDL cholesterol in humans (monotherapy in statin-intolerant patients without baseline lipid lowering therapies) (-20.6% (95% CI, -21.7 to -19.6%)).
“Bempedoic acid monotherapy lowered LDL-C by -20.6% (95% CI, -21.7 to -19.6%) compared with placebo at 6 months.”
Human trialmonotherapy in statin-intolerant patients without baseline lipid lowering therapies180 mg6 monthsn = 8,217
AHA Scientific Sessions 2025 abstract
Bempedoic acid is linked with lower LDL cholesterol in humans (On stable background lipid-lowering therapy) (Median LDL-C reduction 20.1% (IQR 0.0; 39.4)).
“BA alone (20.1%, IQR 0.0; 39.4)”
HumansOn stable background lipid-lowering therapyMedian follow-up of 6.5 monthsn = 108
Real-world efficacy of bempedoic acid: early insights from the BEMPENET Italian Registry
ESC Congress 2026 abstract
Bempedoic acid is linked with lower LDL cholesterol in humans (added to existing lipid-lowering therapy; before-and-after comparison) (mean reduction 31.8 mg/dL; mean patient-level change -17.5%).
“The addition of bempedoic acid significantly reduced LDL-C levels from a mean of 133.6 mg/dL at baseline to 101.8 mg/dL after 3 months (p < 0.001).”
Humansadded to existing lipid-lowering therapy; before-and-after comparisonabout 3 monthsn = 641
Lipids in health and disease
Bempedoic acid is linked with lower LDL cholesterol in humans (-28.8% (121.3 to 86.5 mg/dL)).
“BA significantly reduced total cholesterol (207.4-167.8 mg/dL; -19.1%) and LDL-C (121.3-86.5 mg/dL; -28.8%)”
Humans3 monthsn = 814
Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Journal of clinical lipidology
Bempedoic acid decreases LDL cholesterol in humans (patients with dyslipidemia).
“Currently available treatment options to lower LDL-C with proven cardiovascular benefit include statins, ezetimibe, bempedoic acid, and PCSK9 antibodies.”
Reviewpatients with dyslipidemia
Current atherosclerosis reports
Uric acid
upin humans2+11%
2 studies
Uric acid
upin humans2+11%
Bempedoic acid increases uric acid in humans (+0.96 mg/dL).
“Treatment with BA was associated with an increase in serum uric acid levels (+0.96 mg/dL, p < 0.001), without clinical gout flares.”
Human trialmedian follow-up duration of 28 weeks (IQR 23–47 weeks)n = 118
Journal of clinical medicine
Bempedoic acid is linked with higher uric acid in chronic coronary syndrome patients receiving intensive lipid-lowering therapy.
“BA was well tolerated, with a modest increase in uric acid levels but no gout events and a high treatment persistence rate (94.4%).”
Humansin chronic coronary syndrome patients receiving intensive lipid-lowering therapy180 mg/daymedian follow-up of 28 weeksn = 118
Journal of clinical medicine
Bempedoic acid is linked with higher uric acid in humans (+11.4%).
“Uric acid increased (+11.4%; P < 0.001).”
Humans
Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort
Journal of clinical lipidology
Major adverse cardiovascular events
no changein humans1downin humans1
2 studies
Major adverse cardiovascular events
no changein humans1downin humans1
Bempedoic acid decreases major adverse cardiovascular events in patients with elevated steatosis scores.
“Bempedoic acid reduced MACE4 risk, with an additional benefit in patients with elevated steatosis scores.”
Human trialin patients with elevated steatosis scoresmedian follow-up 40.6 monthsn = 13,970
European journal of preventive cardiology
Bempedoic acid was not clearly linked with major adverse cardiovascular events in humans (MACE-3 incidence: 7.9% versus 9.2%; p=0.338).
“bempedoic acid was not associated with a significant reduction in MACE compared with ezetimibe”
HumansCompared with ezetimibe in statin-intolerant patients with cardiovascular-kidney-metabolic syndrome receiving GLP-1 receptor agonists for secondary prevention1 year
AHA Scientific Sessions 2026 abstract
Mortality
downin humans1no changein humans1RR 0.62–0.87
2 studies
Mortality
downin humans1no changein humans1RR 0.62–0.87
Bempedoic acid showed no clear effect on mortality in humans (hypercholesterolemia) (RR 0.87 (95% CI 0.53–1.43)).
“while CV mortality was unchanged (RR 0.87, 95 % CI 0.53–1.43)”
Human trialhypercholesterolemia
AHA Scientific Sessions 2025 abstract
Bempedoic acid is linked with lower mortality in humans (statin-intolerant hyperlipidemia vs ezetimibe) (2.0% vs 3.3%; RR 0.62, 95% CI 0.55-0.70; HR 0.56, 0.50-0.63; P<0.001).
“bempedoic acid was associated with lower 3-year all-cause mortality (2.0% vs 3.3%; RR 0.62, 95% CI 0.55-0.70; HR 0.56, 0.50-0.63; P<0.001)”
Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years
AHA Scientific Sessions 2026 abstract
Total major adverse cardiovascular events or major adverse limb events
downin humans1−19%
1 study
Total major adverse cardiovascular events or major adverse limb events
downin humans1−19%
Bempedoic acid decreases total major adverse cardiovascular events or major adverse limb events in humans (19%).
“When we consider total, including recurrent, events, the composites of MACE-4+MALE and MACE-3+MALE were reduced by bempedoic acid by 19% (RR, 0.81 [95% CI, 0.73–0.89]; P<0.001) and 18% (RR, 0.82 [95% CI, 0.73–0.92]; P<0.001), respectively, with consistent effects, reaching statistical significance in those with and without PAD (Pinteraction=NS; Table S2”
Human trialmedian of 40.6 monthsn = 13,970
Bempedoic acid reduced leg complications in artery disease
Circulation
Bempedoic acid decreases total major adverse cardiovascular events or major adverse limb events in patients with peripheral artery disease (relative risk 0.71).
“Total MACE-4 or MALE was reduced (relative risk, 0.81 [95% CI, 0.73-0.90]) overall with consistent effects in PAD (relative risk, 0.71 [95% CI, 0.54-0.95])”
Human trialin patients with peripheral artery disease180 mg
Bempedoic acid reduced leg complications in artery disease
Circulation
Total major adverse limb events
downin humans1−45%
1 study
Total major adverse limb events
downin humans1−45%
Bempedoic acid decreases total major adverse limb events in patients with PAD (2.9 with bempedoic acid versus 4.0 with placebo).
“Total, including recurrent, MALE were reduced with bempedoic acid (n/100 patient-years; 2.9 with bempedoic acid versus 4.0 with placebo; RR, 0.55 [95% CI, 0.35–0.85]; P=0.007; Table and Figure ).”
Human trialin patients with PADmedian of 40.6 monthsn = 1,624
Bempedoic acid reduced leg complications in artery disease
Circulation
Bempedoic acid decreases total major adverse limb events in patients with peripheral artery disease (-45%).
“Bempedoic acid reduced total MALE by 45% (relative risk, 0.55 [95% CI, 0.35-0.85]; P=0.007).”
Human trialin patients with peripheral artery disease180 mg
Bempedoic acid reduced leg complications in artery disease
Circulation
Lipids
downin humans1
1 study
Lipids
downin humans1
Bempedoic acid decreases lipids in humans (statin intolerance or unwillingness to take statins).
“The CLEAR clinical trial series established BA's lipid-lowering effect and safety profile”
Reviewstatin intolerance or unwillingness to take statins
Current atherosclerosis reports
Creatine kinase
upin humans1RR 1.13
1 study
Creatine kinase
upin humans1RR 1.13
Bempedoic acid is linked with higher creatine kinase in humans (statin-intolerant hyperlipidemia vs ezetimibe) (10.4% vs 9.2%; RR 1.13, 1.07-1.20; P<0.001).
“creatine kinase elevation (10.4% vs 9.2%; RR 1.13, 1.07-1.20; P<0.001)”
Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years
AHA Scientific Sessions 2026 abstract
New safety signals
no changein humans1
1 study
New safety signals
no changein humans1
Bempedoic acid was not clearly linked with new safety signals in humans across glycaemic subgroups.
“No new safety signals were observed across the glycaemic subgroups.”
Humansacross glycaemic subgroupsBA or BA + ezetimibe fixed dose combination1 year
ESC Congress 2026 abstract
Treatment discontinuation
upin humans1
1 study
Treatment discontinuation
upin humans1
Bempedoic acid increases treatment discontinuation in humans.
“treatment discontinuation was higher with bempedoic acid 180 mg and colesevelam 3.75 g”
Human trial180 mg
Endocrinology, diabetes & metabolism
C-reactive protein
downin humans1
1 study
C-reactive protein
downin humans1
Bempedoic acid decreases C-reactive protein in humans (-34.0% (p < 0.01)).
“The median percentage changes from baseline to week 12 were -13.3% for non-high-density lipoprotein cholesterol (non-HDL-C), -10.8% for total cholesterol, -11.5% for apolipoprotein B, and -34.0% for hsCRP (all p < 0.01).”
Human trial12 weeksn = 180
medRxivPreprint
Non-HDL cholesterol
downin humans1
1 study
Non-HDL cholesterol
downin humans1
Bempedoic acid decreases non-HDL cholesterol in humans (added to background statin therapy, compared with placebo) (MD -15.50 mg/dL; 95% CI -18.95 to -12.04).
“A pooled analysis showed a significant non-HDL-C reduction in the Bempedoic acid group compared to the placebo”
Human trialadded to background statin therapy, compared with placebo12 weeksn = 3,034
AHA Scientific Sessions 2025 abstract
All 23Fewer
What is bempedoic acid linked with?
17Studies link bempedoic acid with 17 measures, among them major adverse cardiovascular events, LDL cholesterol and major adverse cardiovascular events.
Major adverse cardiovascular events
downin humans2HR 0.86
2 studies
Major adverse cardiovascular events
downin humans2HR 0.86
Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (monotherapy in statin-intolerant patients without baseline lipid lowering therapies) (-14% (HR 0.86, 95% CI 0.76-0.97)).
“bempedoic acid monotherapy reduced MACE4 by 14% (HR 0.86; 95% CI, 0.76 – 0.97)”
Human trialmonotherapy in statin-intolerant patients without baseline lipid lowering therapies180 mgn = 8,217
AHA Scientific Sessions 2025 abstract
Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (established ASCVD or high cardiovascular risk).
“CLEAR Outcomes, which further demonstrated fewer major adverse cardiovascular events among patients with established ASCVD or at high cardiovascular risk.”
Reviewestablished ASCVD or high cardiovascular risk
Current atherosclerosis reports
LDL cholesterol
downin humans2
2 studies
LDL cholesterol
downin humans2
Bempedoic acid is associated with LDL cholesterol in humans (Change from baseline in statin-intolerant patients receiving GLP-1 receptor agonists) (16.8 mg/dL reduction from baseline; 113.2 to 96.4 mg/dL).
“to 96.4 mg/dL in the bempedoic acid cohort (AR = 16.8 mg/dL)”
HumansChange from baseline in statin-intolerant patients receiving GLP-1 receptor agonists1 yearn = 748
AHA Scientific Sessions 2026 abstract
Bempedoic acid is associated with LDL cholesterol in humans (hypercholesterolemia or mixed dyslipidemia; with or without other lipid-lowering therapies) (Mean relative reduction: 31.0% in women and 25.3% in men).
“Bempedoic acid, with or without other LLTs, was associated with a >25% reduction in LDL-C in both sexes.”
Humanshypercholesterolemia or mixed dyslipidemia; with or without other lipid-lowering therapiesalone or fixed-dose combination with ezetimibe1 yearn = 2,071
ESC Congress 2026 abstract
Major adverse cardiovascular events
downin humans2RR 0.81–0.88
2 studies
Major adverse cardiovascular events
downin humans2RR 0.81–0.88
Bempedoic acid lowers the risk of major adverse cardiovascular events in humans (hypercholesterolemia) (RR 0.81 (95% CI 0.68–0.96)).
“These changes translated into a 19 % relative reduction in MACE (RR 0.81, 95 % CI 0.68–0.96)”
Human trialhypercholesterolemia
AHA Scientific Sessions 2025 abstract
Bempedoic acid is linked with a lower risk of major adverse cardiovascular events in humans (statin-intolerant hyperlipidemia vs ezetimibe) (10.8% vs 12.3%; RR 0.88, 0.83-0.92; HR 0.81, 0.76-0.85; P<0.001).
“lower 3-point MACE (10.8% vs 12.3%; RR 0.88, 0.83-0.92; HR 0.81, 0.76-0.85; P<0.001)”
Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years
AHA Scientific Sessions 2026 abstract
Major adverse cardiovascular events or major adverse limb events
downin humans1−13%HR 0.87
1 study
Major adverse cardiovascular events or major adverse limb events
downin humans1−13%HR 0.87
Bempedoic acid lowers the risk of major adverse cardiovascular events or major adverse limb events in humans (HR, 0.87 [95% CI, 0.80–0.95]).
“The composite of the trial primary outcome and MALE (MACE-4+MALE) was reduced overall with bempedoic acid (HR, 0.87 [95% CI, 0.80–0.95]; P=0.002; Table S3”
Human trialmedian of 40.6 monthsn = 13,970
Bempedoic acid reduced leg complications in artery disease
Circulation
Bempedoic acid lowers the risk of major adverse cardiovascular events or major adverse limb events in humans (-13%).
“First MACE-4 or MALE was reduced overall by 13% (hazard ratio, 0.87 [95% CI, 0.80-0.95])”
Human trial180 mg
Bempedoic acid reduced leg complications in artery disease
Circulation
Gout
upin humans1RR 1.21
1 study
Gout
upin humans1RR 1.21
Bempedoic acid is linked with a higher risk of gout in humans (statin-intolerant hyperlipidemia vs ezetimibe) (3.7% vs 3.0%; RR 1.21, 1.09-1.34; HR 1.12, 1.01-1.24; P=0.040).
“new or worsening gout (3.7% vs 3.0%; RR 1.21, 1.09-1.34; HR 1.12, 1.01-1.24; P=0.040)”
Humansstatin-intolerant hyperlipidemia vs ezetimibe3 years
AHA Scientific Sessions 2026 abstract
3-point major adverse cardiovascular events
downin humans1HR 0.64
1 study
3-point major adverse cardiovascular events
downin humans1HR 0.64
Bempedoic acid lowers the risk of 3-point major adverse cardiovascular events in humans (High ASCVD risk; compared with no lipid-lowering therapy) (HR 0.64, 95% CI 0.48–0.85).
“bempedoic acid (0.64, 0.48-0.85) and high-intensity statin (0.80, 0.69-0.92) reduced 3-point major adverse cardiovascular events (MACE) vs. no lipid-lowering therapy.”
ReviewHigh ASCVD risk; compared with no lipid-lowering therapy
EClinicalMedicine
Treatment discontinuation
upin humans1
1 study
Treatment discontinuation
upin humans1
Bempedoic acid is associated with treatment discontinuation in humans (171/641 (26.7%)).
“171/641 (26.7%) had discontinued bempedoic acid by follow-up.”
Humansby follow-up, about 3 monthsn = 641
Lipids in health and disease
Suspected adverse events
upin humans1
1 study
Suspected adverse events
upin humans1
Bempedoic acid is associated with suspected adverse events in humans (218/641 (34.0%)).
“Suspected adverse events were documented in 218/641 patients (34.0%)”
Humansup to about 3 monthsn = 641
Lipids in health and disease
Myalgia
downin reviews1
1 study
Myalgia
downin reviews1
Bempedoic acid lowers the risk of myalgia (as reported in the cited network meta-analysis (Xie and colleagues)).
“bempedoic acid ranks best for myalgia risk”
Reviewas reported in the cited network meta-analysis (Xie and colleagues)
Safety of lipid-lowering therapies: it is time for a "DOCebo" effect
Nutrition, metabolism, and cardiovascular diseases : NMCD
Major adverse limb events
downin humans1−36%
1 study
Major adverse limb events
downin humans1−36%
Bempedoic acid lowers the risk of major adverse limb events in patients with PAD (36%).
“In patients with PAD, bempedoic acid reduced the risk of MALE by 36% (5.8% bempedoic acid versus 8.3% placebo; HR, 0.64 [95% CI, 0.44–0.93]; P=0.018; Table and Figure ), translating into an absolute risk reduction of 2.5% at a median of 40 months.”
Human trialin patients with PADmedian of 40.6 monthsn = 1,624
Bempedoic acid reduced leg complications in artery disease
Circulation
Major adverse limb events
downin humans1−36%
1 study
Major adverse limb events
downin humans1−36%
Bempedoic acid lowers the risk of major adverse limb events in patients with peripheral artery disease (-36%).
“Bempedoic acid reduced the risk of MALE by 36% (hazard ratio, 0.64 [95% CI, 0.44-0.93]; P=0.018).”
Human trialin patients with peripheral artery disease180 mg
Bempedoic acid reduced leg complications in artery disease
Circulation
Hyperuricemia
upin humans1RR 1.93
1 study
Hyperuricemia
upin humans1RR 1.93
Bempedoic acid raises the risk of hyperuricemia in humans (hypercholesterolemia) (RR 1.93 (95% CI 1.75–2.14)).
“hyperuricemia risk almost doubled with BA (RR 1.93, 95 % CI 1.75–2.14)”
Human trialhypercholesterolemia
AHA Scientific Sessions 2025 abstract
All 17Fewer
Has bempedoic acid been tested in people?
58 of 117 about agingYes: 7 trials and 22 observational studies in people have been published, and 32 trials are registered.
About aging
Phase 3Completed
Phase 3Terminated
Phase 3Completed
Eze/Simva Switch Study in Diabetics (0653A-807)
Phase 3Completed
Phase 4Terminated
Phase 3Completed
All 40Fewer
Approved
Feb 21, 2020Hypercholesterolemia, heterozygous familial hypercholesterolemia
Apr 1, 2020Hypercholesterolemia, Dyslipidemias, Atherosclerotic Cardiovascular Disease, Hypercholesterolaemia, Mixed Dyslipidaemia
Repurposing
Phase 4Status unknown4 trials
Phase 3Recruiting1 trial
Phase 3Results posted7 trials
Phase 4Recruiting1 trial
ST-elevation myocardial infarction
Phase 4Recruiting1 trial
Phase 4Recruiting1 trial
All 11Fewer
Every condition in trials
Hyperlipoproteinemia type II
Phase 4Completed3 trials
Hyperlipidemias
Phase 3Results posted7 trials
Hyper low density lipoprotein ldl cholesterolemia
Phase 3Results posted2 trials
Readouts due
- Jun 30, 2027
A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid
Phase 3Not yet recruiting
Who is developing bempedoic acid?
3 companies: Daiichi Sankyo, Esperion Therapeutics and Gan & Lee Pharmaceuticals..
Trial sponsors
Company13 trialsPhase 419,916 people
Company6 trialsPhase 4515 people
Zhejiang Otsuka Pharmaceutical
Company4 trialsPhase 3636 people
Company3 trialsPhase 3414 people
Company1 trialPhase 3245 people
Company1 trialPhase 3222 people
Company2 trialsPhase 146 people
Company1 trialPhase 181 people
Funding
1 grant since 2026National Heart, Lung, and Blood Institute$581K
How this record changed
Summary rewritten as its findings changed.
As it read before
Reviews describe lower LDL-C and cardiovascular risk with bempedoic acid in high- and very-high-risk people unable or unwilling to take statins, but increased treatment discontinuation at 180 mg in people with dyslipidemia.
Summary written from the findings.